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Abstract
Background: Cisapride is a prokinetic agent that is useful to relieve gastrointestinal symptoms
that often occur in dialysis patients. However, sudden death has been reported and alarmed the
use of cisapride in dialysis patients. This study was performed to identify whether the use of
cisapride increases the risk of death.
Methods: We retrospectively analyzed all records of dialysis patients followed during the period
November 1997 to March 2000. Cisapride dosage and risk factors associated with increased risk
of sudden death such as cardiovascular disease, hypokalemia, and possible interacting drugs
were recorded.
Results: Of 364 dialysis patients, 85 had been prescribed with cisapride (group A) whereas 279
had not (group B). Group A patients were older, with more female patients and longer duration of
dialysis. There was no significant difference in mortality or causes of death between the two groups
after adjusting for the baseline demographic differences. For group A, eight patients (9.41%) died
while still on cisapride and 19 (22.4%) died after cisapride had been stopped. The causes of death
were peritonitis (n = 2), infection (n = 2), ischemic heart disease (n = 1), malignancy (n = 1), sudden
death (n = 1), and unknown (n = 1). Low serum albumin (p=0.013) and hypokalemia (p=0.066)
were potential predictors of death while taking cisapride, but the presence of diabetes mellitus,
maximum dosage of cisapride, and underlying cardiovascular disease were not. There was no
drug interaction leading to cisapride toxicity.
Conclusions: Patients who were given cisapride were older, more often women, and had a longer
duration of dialysis. Low serum albumin and hypokalemia were significant predictors of death in
patients given cisapride. Although no excessive risk of death was documented, the use of cisapride
in dialysis patients should still be cautious and potential drug interactions and electrolyte
disturbances should be avoided.
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INTRODUCTION
Anorexia, nausea, and dyspepsia are common
gastrointestinal symptoms in uremic patients and would
lead to malnutrition, a significant predictor of mortality.
These symptoms may be related to delayed gastric
emptying, which is frequently seen in patients with
chronic renal failure (1). Cisapride, a prokinetic agent,
is a useful drug to treat these symptoms (2). However,
there have been reported cases of sudden death in patients
taking cisapride. Most of the deaths were related to
cardiac arrhythmia in association with certain drug
combinations (3,4). Similar case reports have also been
described in uremic patients (5) and have alarmed the
use of cisapride in general. The current recommendation
is that caution should be taken with the use of cisapride
in patients with underlying renal failure, cardiac
problems, and electrolyte disturbances. Although it was
withdrawn from the United States market in July 2000
for safety reasons, there was a scarcity of data regarding
mortality and safety of cisapride in dialysis patients.
Because cisapride is an effective drug to treat dyspepsia
and anorexia in uremic patients, we conducted this
retrospective analysis to identify whether prescription
of cisapride is linked to increased risk of death among
dialysis patients and to identify possible factors
associated with increased risk of death.
METHODS
Clinical data of chronic dialysis patients in our renal unit
during the period November 1997 to March 2000 were
retrieved and analyzed retrospectively. Patients were
divided into two groups: those who had been prescribed
with cisapride (group A) and those who had not (group
B) during this period. Demographic factors including age,
sex, presence of diabetes mellitus, mode of dialysis, and
duration of dialysis were recorded. Data including
indications, dosage and duration of cisapride use, and
reasons for stopping cisapride were also obtained. The
primary outcome was death. The causes of death in
patients who died during the study period were also
investigated. To study the risk of deaths associated with
cisapride prescription, dosage of cisapride, concomitant
use of medications including azole antifungals, macrolide
antibiotics, class Ia/III antiarrhythmic agents, tricyclic
antidepressants, antipsychotics and H1 antihistamines,
serum albumin level, coexisting cardiovascular problems,
presence of prolonged QT intervals, and electrolyte
disturbances including hypokalemia and hypocalcemia
were collected in the cisapride group for relative risk
analysis.
Statistical analysis
The SPSS 10.0 program (SPSS, Chicago, IL, US) was
used for statistical analysis. The chi-square test, Fisher's
exact test, and Mann-Whitney's test were used where
appropriate for comparison between various risk factors
and number of deaths. General linear model with
univariate analysis was used for adjustment of potential
confounding factors. Continuous variables were
expressed as mean (SD). A p value of 0.05 was taken as
the level of statistical significance.
RESULTS
There were 364 dialysis patients in the study period
including 314 patients on continuous ambulatory
peritoneal dialysis and 50 patients on hemodialysis. There
were 172 men and 192 women. The mean age was 58.48
(3.52) years and mean duration of dialysis was 54.13
(47.01) months. Among them, 85 patients had been
prescribed with cisapride (group A) whereas 279 had not
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Group A (n = 85) Group B (n = 279) p value
Age, years 63 ± 12 57 ± 14 0.000
Women, n (%) 55 (64.71) 137 (49.10) 0.013
Duration of dialysis, months (median) 21.48 46.00 0.000
Diabetes mellitus, n (%) 30 (35.29) 72 (25.81) 0.088
Peritoneal dialysis/hemodialysis ratio 74:11 240:39 0.808
Table 1. Baseline demographic data for both groups.
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The relationship between potential risk factors related
to death while taking cisapride was analyzed, which
included serum albumin, age, presence of hypokalemia,
maximum cisapride dosage, diabetes mellitus, and
underlying cardiovascular disease. Patients who died
while taking cisapride had a lower serum albumin
compared with other patients from the cisapride group
(27.42 vs 33.32 g/L; p=0.013). Higher serum albumin
was associated with a decreased risk of death (relative
risk, 0.813; p=0.016). There was also a trend that more
patients who died while taking cisapride had
hypokalemia compared with other patients in group A,
although the difference was not statistically significant
(p=0.066). However, the maximum dose of cisapride,
diabetes mellitus, and cardiovascular disease were not
significant predictors of death for patients taking
cisapride (Table 3).
DISCUSSION
Cisapride is a serotonin (5-HT) receptor agonist that is
specifically distributed to the gastric and intestinal tissues
after oral absorption. It improves lower esophageal
sphincter tone, esophageal peristaltic activity, gastric and
duodenal contractility, as well as small bowel transit. It
has also been reported to improve gastric emptying in
dialysis patients (6). It is metabolized by hepatic
cytochrome P450 enzyme. Case reports of sudden death
related to cisapride use had been centered around
prolonged QT interval and fatal cardiac arrhythmias.
Because cardiac disease is the most important cause of
death in dialysis patients on cisapride who would often
present as sudden death (7), it is difficult to incriminate
sudden death to cisapride use unless arrhythmia with
typical QT prolongation or Torsades de pointes is
documented (8,9). In our series, neither of these two
phenomena was observed. There was only one sudden
death in a patient taking cisapride. The number of
cardiovascular or sudden deaths and the overall number
(group B). There were more female patients and a
tendency toward more diabetic patients in group A. They
were also older with a longer duration of dialysis
(Table 1). The most prevalent indication for cisapride
was anorexia (n = 73, 85.9%) followed by dyspepsia (n
= 11, 12.9%) and reflux symptoms (n = 1, 1.2%). The
mean duration of cisapride use was 8.63 months (range,
0.2-56.9 months) and the average daily dosage of
cisapride was 15.76 (6.05) mg. Sixty-eight patients
stopped taking cisapride because it was no longer
indicated, whereas only one patient stopped the drug
because of diarrhea related to cisapride. Twenty-four
patients (28.2%) had underlying cardiovascular disease
in group A. Among them, 17 patients (20%) had ischemic
heart disease, one patient (1.2%) had sick sinus
syndrome, whereas six patients (7.1%) had a history of
cardiac arrhythmia.
Nineteen patients (22.4%) from group A died during the
period and among them eight patients died while still
taking cisapride. In group B, 54 patients (19.4%) died
during follow up. There was no statistically significant
difference in the total number of deaths among the two
groups (p=0.65) after adjusting for age, sex, and duration
of dialysis. The causes of death from both groups were
compared. There were only one cardiac related death and
one sudden death from group A. The causes of death
were similar in both groups as shown in Table 2. As for
concomitant drug usage, 19 patients were taking H1-
antihistamines (hydroxyzine and chlorpheniramine)
concomitantly with cisapride whereas only two patients
had taken antipsychotics (trifluoperazine and haloperidol,
n = 1; pimozide, n = 1) and one patient had taken an
antiarrhythmic agent (amiodarone) with cisapride. No
patient had taken azoles or macrolides concomitantly
with cisapride. No undue side effects were reported. No
prolonged QT interval was found among all the patients
prescribed with cisapride.
Deaths All deaths
While taking cisapride After cisapride cessation Group A Group B p value*
IHD 1 1 2 9 0.520
Sudden death 1 0 1 5 1.000
Peritonitis 2 2 4 8 0.528
Infection 2 3 5 15 0.902
Malignancy 1 0 1 2 1.000
CVA 0 2 2 4 0.647
Fluid overload 0 1 1 0 0.260
Others 0 2 2 5 0.872
Unknown 1 0 1 6 0.457
Total 8 11 19 54 0.651
IHD = ischemic heart disease; CVA = cerebrovascular accident.
*Adjusted for age, sex, and duration of dialysis.
Table 2. Causes of death in both groups.
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of deaths were similar between the two groups.
Our results showed no excessive risk of death in patients
who took cisapride, and no potential drug interactions
could be identified. However, this needs to be interpreted
with caution because of the relatively small sample size
in this retrospective analysis. Furthermore, because this
study was only targeted at identifying the risk of death
associated with cisapride, we have not studied the
incidence of cardiovascular disease in patients not
prescribed with cisapride. Hence, the possibility of a
lower incidence of cardiac disease in group A leading to
the observation of increased mortality in group A cannot
be excluded. Conversely, because cisapride is often
prescribed to malnourished patients with anorexia,
selection bias is a distinct possibility because malnutrition
is a strong predictor of death (10). A prospective study
would give a more definitive answer, but the incidence
of Torsades de pointes is only 1 in 120 000 according to
the pharmaceutical package insert for cisapride, and a
huge study sample size is required for the prospective
study. Under the present stringent recommendation for
cisapride use, it is almost impossible to conduct such a
study. Caution in prescribing cisapride should be
exercised in dialysis patients, and coexisting electrolyte
disturbances and potential drug interactions should be
avoided.
Patients who died while taking cisapride were found to
have lower serum albumin levels and a tendency toward
hypokalemia, both of which may be related to poor intake
and malnutrition in this group of patients. There have
been previous recommendations that uncorrected
electrolyte disturbance should be avoided because it may
increase the risk of Torsade de pointes during cisapride
use (11). Given the fact that most deaths were not related
to sudden death or cardiac arrhythmia in our series, the
mortality in the cisapride group may be associated with
the effects of poor nutrition or hypokalemia per se rather
than the use of cisapride. It is established that malnutrition
has adverse effects on survival (12,13). Our findings
should alert caution in prescribing cisapride in patients
with underlying malnutrition or tendency for
hypokalemia because both are expected to be more
Potential risk factors
Patients who died while Other patients given
p value
taking cisapride (n = 8) cisapride (n = 77)
Age, years 66.51 ± 8.14 62.85 ± 12.19 0.416
Diabetes mellitus, n (%) 4 (50) 26 (33.77) 0.444
Serum albumin, g/L 27.42 ± 4.93 33.32 ± 5.06 0.013
Hypokalemia, n (%) 6 (75) 30 (39.90) 0.066
Concomitant heart problem, n (%) 3 (37.5) 21 (27.27) 0.682
Maximum cisapride dose, mg 15.97 ± 6.28 13.75 ± 2.31 0.450
Table 3. Potential predictors of death while taking cisapride.
common in this group of patients indicated for prokinetic
agents.
In conclusion, no excessive risk of death was
demonstrated for the use of cisapride in dialysis patients
from our review. However, given the rare but potentially
fatal cardiac complications associated with cisapride, its
prescription in dialysis patients should still be cautious,
and potential drug interactions and electrolyte
disturbances should be avoided as far as possible.
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